PAVmed sets third-quarter update date amid absence of verified financial results
Key Facts
PAVmed scheduled its third-quarter business update and results discussion for November 13, 2026, at 8:30 a.m. Eastern time, according to an investor relations announcement. The date is the same day the story covered the company's results, but third-quarter figures attributed to the company did not appear on its open official results page. The value of the per-share loss or the amount by which it exceeded analysts' expectations could not be verified from an available reliable source. The company announced the call date through its official statement on October 30. PAVmed describes its business as spanning medical devices, diagnostics and digital health.
The latest published financial results available for reference are from the second quarter of 2026. In that quarter, the company reported a net loss attributable to common shareholders of about $5.5 million, or diluted loss of $0.87 per share under GAAP. Adjusted non-GAAP loss was about $1.7 million, or $0.27 per share. The company says adjusted measures do not replace the corresponding GAAP accounting measures. The difference between the two figures underscores the need to distinguish between the measurement bases when reading the company's results.
PAVmed had about $3.8 million in cash and cash equivalents on June 30, 2026, compared with $1.5 million on December 31, 2025. In its diagnostics business, the company said Lucid Diagnostics recorded $1.5 million in revenue from its EsoGuard test in the second quarter and processed 2,770 tests. These figures provide context on liquidity and commercial activity ahead of the scheduled third-quarter update. For the year-on-year comparison, EsoGuard revenue was $1.2 million in the third quarter of 2025, with 2,841 tests processed during that quarter. PAVmed also said in its 2025 results that the ability of the company and Lucid to raise additional financing when needed was among the risks affecting future operations.
Product plans include different regulatory pathways at the subsidiaries. PAVmed said Veris Health continues to develop an implantable physiological monitoring device, targeting an FDA 510(k) submission in early 2027. For PortIO, the company said a request for an FDA meeting was planned during the fourth quarter of 2026. In its third-quarter 2025 update, the chief executive said the company was entering the final stages of a process he said had lasted 18 months to stabilize its structure and strengthen its balance sheet. The November 13 update remains the announced date for discussing third-quarter business and results.